ReviewGene therapy2009
Progress and prospects: prospects of repeated pulmonary administration of viral vectors.
Review in Gene therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Novel Immune Response Evasion Strategy to Redose Adeno-associated Viral Vectors and Prolong Survival in Surfactant Protein-B-Deficient Mice.American journal of respiratory cell and molecular biology · 2025Article
- Article
- Exosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity.The Journal of biological chemistry · 2021Article
- Genetic Delivery and Gene Therapy in Pulmonary Hypertension.International journal of molecular sciences · 2021Review
- Breaching the Delivery Barrier: Chemical and Physical Airway Epithelium Disruption Strategies for Enhancing Lentiviral-Mediated Gene Therapy.Frontiers in pharmacology · 2021Article
- Gene Therapy for Respiratory Diseases: Progress and a Changing Context.Human gene therapy · 2020Article
- BIOPHYSICS MEETS GENE THERAPY: HOW EXPLORING SUPERCOILING-DEPENDENT STRUCTURAL CHANGES IN DNA LED TO THE DEVELOPMENT OF MINIVECTOR DNA.Technology and innovation · 2019Article
- In utero gene editing for monogenic lung disease.Science translational medicine · 2019Article
- Lessons learned from lung and liver in-vivo gene therapy: implications for the future.Expert opinion on biological therapy · 2018Review
- Article
- Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Lung gene therapy-How to capture illumination from the light already present in the tunnel.Genes & diseases · 2014Article
- Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier.Journal of controlled release : official journal of the Controlled Release Society · 2014Article
- Intrapulmonary Versus Nasal Transduction of Murine Airways With GP64-pseudotyped Viral Vectors.Molecular therapy. Nucleic acids · 2013Article
- Gene therapy: light is finally in the tunnel.Protein & cell · 2011Review
- Proteostasis: a new therapeutic paradigm for pulmonary disease.Proceedings of the American Thoracic Society · 2011Article
- Neonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus-based vector.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Ectopic Expression of HumanAvicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Pulmonary gene therapy may ultimately cure diseases such as cystic fibrosis, alpha1-antitrypsin deficiency, lung cancer and pulmonary hypertension. Efficient expression of delivered genes in target cell types is essential for the achievement of this goal. To this end, re-administration of viral vectors may be required (1) to increase the percentage of transduced airway epithelial cells, (2) to direct gene transfer to individual lobes during successive delivery sessions or (3) to boost attenuated expression over time. Immune responses to viral proteins or viral-encoded proteins are the greatest barrier to repeated vector administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.